Mark Ahn (via PR Newswire)
February 8, 2021 10:45 AM EST
People
Pharma

For­mer Gale­na chief Mark Ahn back in hot wa­ter as DOJ lev­els in­sid­er trad­ing charges for con­sul­tant work

Kyle Blankenship

When Mark Ahn de­part­ed trou­bled Gale­na Phar­ma­ceu­ti­cals back in 2014, he told in­vestors he look­ing to pur­sue oth­er “long-held” goals. Turns out one of those …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times